Senthurselvi Ramamoorthy
Research Subjects
Research Interests
Senthurselvi Ramamoorthy has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Abiraamasundari Ramapalaniappan
SpinoS Life Science Research and Private Limited, Thudiyalur, Tamil Nadu, India
1 shared publication Bhuvaneswari K
Department of Pharmacology, PSG institute of Medical Sciences and Research, The Tamilnadu Dr.MGR Medical University, Coimbatore, India, 641004
1 shared publication- Prabakaran Desomayanandanam
In vitro Research Solutions Pvt Ltd, Bangalore, Karnataka, India
1 shared publication - Rajat Shah
Nutriventia Private Limited, Mumbai, Maharashtra, India
1 shared publication - Shefali Thanawala
Nutriventia Private Limited, Mumbai, Maharashtra, India
1 shared publication
Latest Publications
- Open Access
- 2 January 2023
- Published by Taylor & Francis in Journal of Dietary Supplements
- Vol. 21 (1) , 13-27
Comparative Bioavailability and Benefits on Mental Functions of Novel Extended-Release Caffeine Capsules against Immediate-Release Caffeine Capsules: An Open-Label, Randomized, Cross-over, Single-Dose Two-Way Crossover Study
Present study aimed compared pharmacokinetic profile of sustained-release CaffXtend® capsules (SR-Caffeine) with immediate-release caffeine capsules (IR-Caffeine), and the effect of SR-caffeine on memory, motivation, concentration, and attention. This open-label, randomized, single-dose, two-treatment, two-sequence, two-period, two-way crossover oral bioavailability study block randomized (1:1) healthy subjects (N = 15) to receive SR-Caffeine (200 mg) and IR-Caffeine (200 mg). Blood samples were collected at 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 and 48 h in each period. Primary study outcome included comparing relative bioavailability of SR-Caffeine 200 mg and IR-Caffeine 200 mg under fasting conditions, and changes in caffeine research visual analogue scale (Caff-VAS) scores (‘relaxed’, ‘alert’, ‘jittery’, ‘tired’, ‘tense’, ‘headache’, ‘overall mood’ and ‘mentally fatigued’) were also evaluated. Fifteen subjects completed the study. Mean tmax was 4.08 ± 2.13h for SR-Caffeine compared to 0.83 ± 0.39h for IR-Caffeine, (p < 0.0001). Similarly, mean t½ was 7.07 ± 3.48h for SR-Caffeine compared to 5.78 ± 2.11h for IR-Caffeine (p = 0.04189). However, total exposure was similar for SR-Caffeine and IR-Caffeine (90% CI: 89.89–120.50% to 94.49–123.82% for geometric least square mean of ln-transformed AUC0-t and AUC0-∞). In the Caff-VAS evaluation, the SR-Caffeine group showed significantly better scores for ‘jitteriness’, ‘tiredness’, ‘alertness’ and ‘overall mood’ for 8–12 h than the IR-Caffeine group. No adverse events were reported. Results demonstrated sustained release of caffeine over 24 h from SR-Caffeine as compared to IR-Caffeine, which showed significant improvements in the scores for ‘relaxed’, ‘alertness’ and ‘overall mood’ and significantly lower scores for the parameters-‘jittery’ and ‘tired’ for extended period. Clinical trial registration: CTRI/2021/06/034185
- 2 January 2023
- Published by Taylor & Francis in Journal of Dietary Supplements
- Vol. 21 (1) , 13-27
Open AccessComparative Bioavailability and Benefits on Mental Functions of Novel Extended-Release Caffeine Capsules against Immediate-Release Caffeine Capsules: An Open-Label, Randomized, Cross-over, Single-Dose Two-Way Crossover Study
Present study aimed compared pharmacokinetic profile of sustained-release CaffXtend® capsules (SR-Caffeine) with immediate-release caffeine capsules (IR-Caffeine), and the effect of SR-caffeine on memory, motivation, concentration, and attention. This open-label, randomized, single-dose, two-treatment, two-sequence, two-period, two-way crossover oral bioavailability study block randomized (1:1) healthy subjects (N = 15) to receive SR-Caffeine (200 mg) and IR-Caffeine (200 mg). Blood samples were collected at 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 and 48 h in each period. Primary study outcome included comparing relative bioavailability of SR-Caffeine 200 mg and IR-Caffeine 200 mg under fasting conditions, and changes in caffeine research visual analogue scale (Caff-VAS) scores (‘relaxed’, ‘alert’, ‘jittery’, ‘tired’, ‘tense’, ‘headache’, ‘overall mood’ and ‘mentally fatigued’) were also evaluated. Fifteen subjects completed the study. Mean tmax was 4.08 ± 2.13h for SR-Caffeine compared to 0.83 ± 0.39h for IR-Caffeine, (p < 0.0001). Similarly, mean t½ was 7.07 ± 3.48h for SR-Caffeine compared to 5.78 ± 2.11h for IR-Caffeine (p = 0.04189). However, total exposure was similar for SR-Caffeine and IR-Caffeine (90% CI: 89.89–120.50% to 94.49–123.82% for geometric least square mean of ln-transformed AUC0-t and AUC0-∞). In the Caff-VAS evaluation, the SR-Caffeine group showed significantly better scores for ‘jitteriness’, ‘tiredness’, ‘alertness’ and ‘overall mood’ for 8–12 h than the IR-Caffeine group. No adverse events were reported. Results demonstrated sustained release of caffeine over 24 h from SR-Caffeine as compared to IR-Caffeine, which showed significant improvements in the scores for ‘relaxed’, ‘alertness’ and ‘overall mood’ and significantly lower scores for the parameters-‘jittery’ and ‘tired’ for extended period. Clinical trial registration: CTRI/2021/06/034185
- Open Access
- 22 November 2019
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 12 (04) , 1975-1983
A Cross Sectional Study on the Status of Inflammatory Markers in Polycystic Ovary Syndrome (Pcos) in Indian Population
Polycystic Ovarian Syndrome (PCOS) is a common disease exclusively seen in women of reproductive age group. World Health Organization reports that Polycystic Ovarian Syndrome approximately affects 5-10% of the reproductive female population worldwide. Women with PCOS have chronic inflammation. This in turn leads to increased incidence of non-communicable diseases like cardiovascular disease and diabetes2. Chronic inflammation in PCOS patients can be identified using serum markers such as C - reactive protein [CRP], Interleukin-6 [IL-6] and Interleukin-18 [IL-18].So the main objective of the study was to assess the status of inflammation in patients with Polycystic Ovary Syndrome (PCOS) and to assess the influence of drugs prescribed for PCOS on inflammation. Patients were divided into three groups as healthy volunteers, newly diagnosed PCOS patients, already on treatment patients for PCOS. High sensitivity CRP (hs-CRP), IL-6 and IL-18 were assessed. There was an increase in the hs-CRP, IL-6 and IL-18 compared to healthy volunteers in both newly diagnosed and already diagnosed groups. But there was no statistical significance (hs-CRP=0.975, IL-6=0.746, IL-18 = 0.148) between them. The mean value has decreased in the already on treatment group as duration of treatment increases. There was no statistical significance between them. There was an inversely proportional relationship between the mean values of inflammatory markers and duration of treatment.
- 22 November 2019
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 12 (04) , 1975-1983
Open AccessA Cross Sectional Study on the Status of Inflammatory Markers in Polycystic Ovary Syndrome (Pcos) in Indian Population
Polycystic Ovarian Syndrome (PCOS) is a common disease exclusively seen in women of reproductive age group. World Health Organization reports that Polycystic Ovarian Syndrome approximately affects 5-10% of the reproductive female population worldwide. Women with PCOS have chronic inflammation. This in turn leads to increased incidence of non-communicable diseases like cardiovascular disease and diabetes2. Chronic inflammation in PCOS patients can be identified using serum markers such as C - reactive protein [CRP], Interleukin-6 [IL-6] and Interleukin-18 [IL-18].So the main objective of the study was to assess the status of inflammation in patients with Polycystic Ovary Syndrome (PCOS) and to assess the influence of drugs prescribed for PCOS on inflammation. Patients were divided into three groups as healthy volunteers, newly diagnosed PCOS patients, already on treatment patients for PCOS. High sensitivity CRP (hs-CRP), IL-6 and IL-18 were assessed. There was an increase in the hs-CRP, IL-6 and IL-18 compared to healthy volunteers in both newly diagnosed and already diagnosed groups. But there was no statistical significance (hs-CRP=0.975, IL-6=0.746, IL-18 = 0.148) between them. The mean value has decreased in the already on treatment group as duration of treatment increases. There was no statistical significance between them. There was an inversely proportional relationship between the mean values of inflammatory markers and duration of treatment.